TABLE 1.

Summary of donor and recipient screening practices

Countrya	Deceased donor screening	Living donor screening	Pretransplant recipient screening	Specimen type
Canadab	Universal NAT	Universal NAT	Clinical	NP or BAL
Switzerland	Universal NAT	Universal NAT	Clinical	NP or BAL
Italy	Universal NAT	Universal NAT	Clinical	BAL in deceased donor NP in living donor
Spain	Universal NAT	Universal NAT; donation postponed 21 d if known exposure	Clinical	NP ± BAL
Koreab	Universal NAT	Universal NAT	Universal NAT	NP
Japanb	Risk-based NAT due to limited testing capacity	Self-isolation or hospital admission 14 d prior to surgery	Clinical; NAT where testing available	NP (and BAL for intubated patients)

Abbreviations: BAL, bronchoalveolar lavage; NAT, nucleic acid testing; NP, nasopharyngeal.

^aMay represent the author centers—not necessarily country wide; assumes transplant activity is continuing.

^bRecommendations of country-specific transplant societies.